03 October 2013 | News | By BioSpectrum Bureau
Mystic Pharma gets notices of allowance from China for its Deep Draw Container Forming Method and Japan for its Combination Unit Dose Dispensing Container
Singapore: Mystic Pharmaceuticals, US, received key notices of allowance from Asian patent offices in the company's ongoing initiative to secure worldwide control over its novel designs.
The company reported that it has received patent application notices from both the China patent office for its 'Deep Draw Container Forming Method' and the Japan patent office for its 'Combination Unit Dose Dispensing Container' patent applications.
Mr Timothy Sullivan, president and CEO, Mystic, said that, "Over the past decade Mystic has innovated packaging and delivery technologies that enable the development of patient-centric pharmaceutical products. Japan and China along with several other global markets are high priority strategic opportunities for Mystic enhanced pharmaceutical drug/device combined products."
He further added, "These latest international patents reflect our long term commitment to developing the global market opportunity for our technology and products."
Mystic's VersiDoser and VRx2 delivery platforms utilize novel unit dose packaging and patient-centric dispensers that can be configured for precision self-administration of therapeutics for ophthalmic, systemic nasal, nose to brain, sublingual, oral and dermal applications, he added.